Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Pembrolizumab Added to Best Supportive Care Extends Survival in Patients with Hepatocellular Carcinoma

TOP - May 2022 Vol 15, No 3 - ASCO GI 2022 Highlights

Pembrolizumab (Keytruda) added to best supportive care (BSC) improved outcomes including overall survival (OS) versus BSC alone in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib (Nexavar), according to final results from the KEYNOTE-394 trial.

Patients treated with pembrolizumab plus BSC had a median OS of 14.6 months (95% confidence interval [CI], 12.6-18.0) compared with 13.0 months (95% CI, 10.5-15.1) for those treated with placebo plus BSC, corresponding to a 21% reduction in the risk for death in the pembrolizumab group (hazard ratio [HR], 0.79; P = .0180), reported Shukui Qin, MD, Director, Cancer Center of Jinling Hospital, Nanjing Chinese Medicine University, China, at the 2022 ASCO Gastrointestinal Cancers Symposium.

“These data reinforce the benefit–risk balance for pembrolizumab observed in globally conducted studies in the second-line treatment of advanced HCC and provide support for the generalizability of data worldwide,” said Dr Qin.

“Although globally-approved antiangiogenic therapy has improved clinical outcomes in the second-line treatment setting, available treatment options benefit a minority of patients. There is a high unmet medical need for therapies that prolong survival and are tolerable,” he said. “Pembrolizumab demonstrated efficacy and a manageable adverse event [AE] profile in sorafenib-treated patients with advanced HCC in the global phase 2 and 3 studies KEYNOTE-224 and KEYNOTE-240, respectively, though prespecified statistical significance criteria for OS and progression-free survival were narrowly missed in KEYNOTE-240.”

Study Details

KEYNOTE-394 was a double-blind phase 3 trial of 453 Asian patients with advanced HCC previously treated with sorafenib or oxaliplatin (Eloxatin)-based chemotherapy. Patients (N = 300) were randomized to pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles (approximately 2 years) plus BSC consisting of pain management and management of other potential complications (including ascites per local standards of care) or placebo plus BSC.

Approximately three-fourths of patients in both arms had extrahepatic spread of their cancer and 11% had macrovascular invasion. Some 90% received sorafenib as first-line treatment and 9% received oxaliplatin-based chemotherapy.

A total of 50.7% of patients in the pembrolizumab arm and 66.7% of those in the placebo arm received a systemic anticancer therapy after discontinuation of study treatment, and 20.7% and 28.1%, respectively, previously received a PD-1 or PD-L1 inhibitor, Dr Qin noted.

The 24-month OS rate was 34.3% in the pembrolizumab arm versus 24.9% in the placebo arm. Median progression-free survival was 2.6 months with pembrolizumab plus BSC compared with 2.3 months with BSC alone (HR, 0.74; P = .0032).

A meta-analysis of data from KEYNOTE-394 and KEYNOTE-240 showed a median OS of 14.2 months in patients randomized to pembrolizumab versus 12.5 months in those randomized to placebo (HR, 0.79; 95% CI, 0.67-0.93). KEYNOTE-240 also compared pembrolizumab and BSC with placebo and BSC in patients with advanced HCC treated previously with sorafenib. However, as Dr Qin mentioned, it narrowly missed statistical significance per specified criteria.

The objective response rate in the pembrolizumab arm was 12.7% compared with 1.3% in the placebo arm (P <.0001). There were 6 (2.0%) complete responses in the pembrolizumab arm versus 1 (0.7%) in the placebo arm. The median duration of response was 23.9 and 5.6 months, respectively.

Safety Profile

The AE profile of pembrolizumab was manageable and consistent with previous reports in this patient population.

Treatment-related AEs occurred in 66.9% of patients in the pembrolizumab plus BSC arm and 49.7% of those in the placebo plus BSC arm. Grade 3 to 5 treatment-related AEs occurred in 14.4% of patients who received pembrolizumab and 5.9% of those who received placebo. Immune-mediated AEs of any grade occurred in 18.1% and 10.5% of patients, respectively, with grade 3 to 5 immune-mediated AEs occurring in 3.0% of those randomized to pembrolizumab. There were 3 deaths due to gastrointestinal hemorrhage, autoimmune hepatitis, and soft tissue infection in the pembrolizumab arm related to the study medication.

Related Items
Experts Discuss the Evolving Role of Telemedicine in Oncology Care
William King
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Telemedicine
Ibrutinib Added to Standard-of-Care Therapy Improves Progression-Free Survival in Older Patients with MCL
William King
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in ASCO 2022 Highlights
Updated NCCN Guidelines Lower Age for Initial Colorectal Cancer Screening
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
New Treatment Strategies for Patients with Advanced Melanoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
The Future of Genetic Therapies and Value-Based Care in Oncology
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Community Provider Perspective: The Current and Future State of Cancer Care
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Last modified: May 6, 2022